Skip to main content

Advertisement

Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation

Fig. 7

Antitumor activity of EE02 in an H460 xenograft model. a H460 cells (5 × 106 per flank) were injected into the right flank of mice. When the volume of the tumors reached 50 mm3, the mice were randomly divided into four groups (6 mice in each group). Then, DMSO (negative control), low-dose EE02 (5 mg/kg b.w.), high-dose EE02 (10 mg/kg b.w.) or erlotinib (positive control, 10 mg/kg b.w.) was intraperitoneally injected into the mice every other day. b The volume of each tumor was measured every other day for 20 days. c The body weights of the mice are shown. d The volume of each tumor was measured after tumor extraction at the experimental endpoint. e The tumors excised from the mice after 20 days of treatment are shown. f The expression of Akt, p-Akt, Erk, p-Erk and ki67 in the tumor tissue at the end of the experiments were assessed using IHC staining

Back to article page